How to Get Vyleesi (Bremelanotide) in Virginia

Who Can Prescribe Vyleesi in Virginia

Any Virginia-licensed prescriber with authority to write for scheduled or legend drugs can prescribe bremelanotide. This includes physicians (MD and DO), nurse practitioners, and physician assistants. Virginia grants full practice authority to NPs who have completed a supervised practice period, meaning many NPs can prescribe Vyleesi independently without a collaborating physician agreement.

A prescriber will typically confirm an HSDD diagnosis using criteria from the DSM-5, which requires persistent or recurrent deficiency of sexual desire that causes marked distress and is not better explained by another medical condition, substance use, or relationship factors. The ISSWSH process-of-care guidelines recommend a biopsychosocial assessment before initiating pharmacotherapy. Your clinician should also review your medication list, because SSRIs, hormonal contraceptives, and other drugs can independently suppress desire.

Bremelanotide is not a controlled substance in Virginia. It carries no DEA scheduling restrictions, so it does not require the additional monitoring protocols that apply to opioids or benzodiazepines. This simplifies the prescribing workflow considerably.

Telehealth Access in Virginia

Virginia law permits telehealth prescribing for Vyleesi, and multiple platforms now offer remote consultations for HSDD. A telehealth visit for bremelanotide follows the same clinical standards as an in-person appointment. The prescriber must establish a provider-patient relationship, take a medical history, confirm the HSDD diagnosis, and document the clinical rationale.

Virginia's telehealth parity law (Va. Code § 38.2-3418.16) requires commercial insurers to cover telehealth services at the same reimbursement rate as in-person visits, which means the consultation itself should not cost more when done remotely. After the visit, your prescriber sends the prescription electronically to a pharmacy of your choice, including specialty or compounding pharmacies that ship within the state.

The typical telehealth timeline from initial consultation to first injection runs 7 to 14 days. That window accounts for the visit itself (often scheduled within 48 hours), electronic prescription transmission, any required prior authorization, and pharmacy dispensing or shipping. If no prior authorization is needed, the turnaround can be as short as 3 to 5 business days.

For patients in rural parts of Virginia where specialists are scarce, telehealth eliminates travel to urban centers like Richmond, Norfolk, or Northern Virginia. The American College of Obstetricians and Gynecologists has endorsed telehealth as an appropriate modality for sexual health consultations that do not require a physical exam.

What Labs and Screening Are Needed Before Starting

Vyleesi does not require routine laboratory monitoring, but a baseline workup helps rule out medical causes of low desire that would warrant a different treatment approach. Most prescribers in Virginia will order the following before writing the prescription:

Thyroid panel (TSH and free T4). Hypothyroidism is a well-documented cause of decreased libido in premenopausal women. A 2018 review in the Journal of Clinical Endocrinology & Metabolism found that subclinical hypothyroidism affected sexual function scores in 40% to 60% of affected women. Treating the thyroid disorder first may resolve the desire complaint entirely.

Prolactin level. Hyperprolactinemia suppresses gonadotropin-releasing hormone and can blunt desire. If prolactin is elevated, imaging or medication adjustment comes before HSDD pharmacotherapy.

Metabolic panel and CBC. These are general-health screens that help identify anemia, renal impairment, or hepatic dysfunction. The FDA-approved labeling for Vyleesi notes that bremelanotide has not been studied in patients with severe hepatic or renal impairment, so clinicians should exercise judgment in those populations.

Depression screening. Since HSDD and depression share overlapping symptoms, a validated tool like the PHQ-9 helps distinguish between the two. The DSM-5 diagnostic criteria for HSDD explicitly require that the distress is not better accounted for by a nonsexual mental disorder.

Blood pressure measurement is also standard. The FDA label carries a warning about transient blood pressure increases: in the RECONNECT trial, mean systolic blood pressure rose approximately 2 to 3 mmHg after injection. Patients with uncontrolled hypertension or significant cardiovascular disease should discuss risks with their prescriber before starting.

The RECONNECT Trial: Clinical Evidence Behind Vyleesi

The FDA approved bremelanotide based primarily on the RECONNECT studies, two randomized, double-blind, placebo-controlled phase 3 trials enrolling 1,247 premenopausal women with HSDD. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated sexual activity.

Results were statistically significant but modest. The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and change in the Female Sexual Function Index (FSFI) desire domain score. The treatment group showed a mean FSDS-DAO improvement of -0.7 points compared with placebo. The FSFI desire domain improved by 0.5 points over placebo. Both differences met the prespecified threshold for clinical significance.

The most common adverse event was nausea, affecting approximately 40% of patients in the treatment group versus 1% in the placebo group. Nausea was dose-dependent and typically occurred within 30 minutes of injection. It diminished with repeated dosing in most women. About 13% of bremelanotide-treated patients discontinued the trial due to adverse events, compared with 2% in the placebo arm.

Dr. Sheryl Kingsberg, a principal investigator on the RECONNECT trials, noted: "HSDD is a real medical condition that affects millions of women, and bremelanotide offers a mechanism of action entirely different from flibanserin. Having two FDA-approved options with distinct pharmacologies gives clinicians and patients meaningful choice."

One clinical detail worth noting: bremelanotide works through melanocortin-4 receptor agonism in the central nervous system, a pathway distinct from flibanserin's serotonin receptor modulation. This means women who did not respond to flibanserin (Addyi) may still respond to bremelanotide, and vice versa. The FDA label does not restrict use based on prior flibanserin failure.

Virginia Medicaid and Commercial Insurance Coverage

Virginia Medicaid covers Vyleesi with prior authorization for premenopausal women diagnosed with HSDD. The prior authorization process requires documentation that confirms several criteria:

1. The patient is a premenopausal adult female.
2. The HSDD diagnosis meets DSM-5 criteria.
3. The low desire is not explained by a coexisting medical condition, substance, medication, or relationship problem.
4. The prescriber has conducted or reviewed appropriate screening (depression, thyroid, medication review).

Most Virginia Medicaid managed care organizations (MCOs), including Aetna Better Health of Virginia, Anthem HealthKeepers, and Molina Healthcare, follow the Department of Medical Assistance Services (DMAS) preferred drug list. Bremelanotide may sit on a non-preferred tier, which triggers the prior authorization requirement. Approval turnaround is typically 48 to 72 hours for standard requests and 24 hours for urgent requests.

Commercial insurance coverage varies widely. Some plans cover Vyleesi under the pharmacy benefit with a specialty-tier copay. Others exclude it entirely. A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that prior authorization approval rates for HSDD medications ranged from 50% to 75% depending on the payer, with denials most often citing insufficient documentation rather than medical inappropriateness.

If your insurer denies coverage, your prescriber can submit a peer-to-peer review or a formal appeal with supporting clinical notes. Palatin Technologies also maintains a patient assistance program for eligible uninsured or underinsured women.

Prior Authorization Documentation in Virginia

A complete prior authorization submission for Vyleesi in Virginia typically includes:

The prescriber's clinical notes confirming an HSDD diagnosis. These should document the onset, duration, and severity of symptoms, along with the degree of personal distress. Insurers expect specific language referencing DSM-5 criteria rather than vague descriptors like "low libido."

A medication reconciliation showing that the patient is not taking a drug known to cause decreased desire as a side effect. SSRIs, SNRIs, hormonal contraceptives, antipsychotics, and antiandrogens are the most commonly flagged agents. If the patient is on one of these medications and the prescriber still considers HSDD the appropriate diagnosis, a brief clinical justification explaining why the medication is not the primary cause is helpful.

Lab results, if obtained. Though not universally required, including a normal TSH, prolactin, and CBC strengthens the submission and reduces the chance of a request for additional information, which delays approval.

A completed prior authorization form from the specific MCO or pharmacy benefit manager. Each insurer has its own form. The Virginia Association of Health Plans maintains a standardized prior authorization form template, but most payers still require their proprietary version.

503A Compounding Pharmacies in Virginia

Virginia licenses 503A compounding pharmacies under the Virginia Board of Pharmacy, and these facilities can compound bremelanotide for patients with valid prescriptions. A compounded version may cost less than the branded Vyleesi product, particularly for patients paying out of pocket.

There is an important distinction between 503A and 503B pharmacies. A 503A pharmacy compounds medications based on individual patient prescriptions. A 503B outsourcing facility compounds without patient-specific prescriptions and is subject to FDA inspection. Both types operate in Virginia, but for bremelanotide specifically, 503A pharmacies are the more common route for individual patients.

Compounded bremelanotide should match the FDA-approved dose of 1.75 mg per injection. Patients should confirm with their compounding pharmacy that the product undergoes potency testing and sterility verification. The Virginia Board of Pharmacy requires 503A pharmacies to comply with USP 797 standards for sterile compounding, which includes environmental monitoring, personnel training, and beyond-use dating protocols.

Out-of-pocket pricing for compounded bremelanotide in Virginia typically ranges from $50 to $150 per month depending on the number of doses, compared with the branded Vyleesi list price of approximately $900 per month (for 8 autoinjectors). This price difference makes compounding an attractive option for women whose insurance does not cover the brand product.

Transferring a Vyleesi Prescription to Virginia

If you are moving to Virginia or splitting time between states, you can transfer an existing Vyleesi prescription. Virginia accepts prescription transfers from all 50 states under standard pharmacy transfer protocols. Your current pharmacy contacts the receiving Virginia pharmacy, verifies the prescription details, and transfers the remaining refills.

For telehealth patients, the prescribing provider must hold a Virginia medical license (or be practicing under a multistate compact license) to write prescriptions filled in Virginia. If your current telehealth provider is not licensed in Virginia, you will need to establish care with a Virginia-licensed prescriber. The Interstate Medical Licensure Compact, which Virginia participates in, can expedite this process for physicians seeking multistate licensure.

Controlled-substance transfer rules do not apply to bremelanotide because it is unscheduled. The process is the same as transferring any non-controlled legend drug.

What to Expect After Your First Injection

The first dose of Vyleesi is sometimes administered in a clinical setting so the prescriber can monitor blood pressure and observe for nausea. After that, patients self-administer at home using a prefilled autoinjector (branded product) or a standard insulin syringe (compounded product).

Inject subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours or more than 8 doses in a calendar month per FDA labeling.

Nausea management is practical. In RECONNECT, 40% of women experienced nausea with their first doses, but this dropped to approximately 20% to 25% with continued use. Taking an over-the-counter antiemetic like ondansetron (if prescribed) or dimenhydrinate 30 minutes before the bremelanotide injection can help. Eating a light meal before dosing also reduces gastric distress.

Focal skin darkening at the injection site or on the face and gums has been reported in about 1% of patients. This hyperpigmentation is related to bremelanotide's melanocortin activity and is generally reversible after discontinuation, though resolution may take several months. The FDA label recommends that patients with dark skin tones monitor for changes and report them to their prescriber.

Patients using hormonal contraceptives should be aware that bremelanotide can slow the absorption of orally administered medications due to its effect on gastrointestinal motility. The FDA recommends administering oral contraceptives at least 1 hour before or 2 hours after a bremelanotide injection to avoid reduced contraceptive efficacy.